Peer Schatz on Qiagen s Emerging Protein Offerings and Acquisition Strategy | GenomeWeb

Qiagen has been among the most aggressive acquirers in the multi-platform molecular biology tools space. The firm has made six acquisitions since April, with a particular focus on proteomics and molecular diagnostic applications. This week, Qiagen CEO Peer Schatz spoke with BioCommerce Week about the firm's rapidly expanding portfolio and its acquisition strategy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."